Drugs / Recombinant Human Prourokinase
Recombinant Human Prourokinase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03108833 | Jun 2017 → Dec 2019 | pulmonary embolism | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Prourokinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03108833 ↗ |
| Action | Activate | “Recombinant human prourokinase (rhPro-UK) is a novel plasminogen activator” PMID 41916317 ↗ Mar 2026 |
| Modality | Protein / enzyme biologic | “Recombinant human prourokinase (rhPro-UK) is a novel plasminogen activator” PMID 41916317 ↗ Mar 2026 |
| Route | Intravenous | “intravenous rhPro-UK” PMID 41916317 ↗ Mar 2026 |